Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a greater percentage of glucose time in range compared with the use of a sensor-augmented insulin pump. Over the past decade, randomised controlled trials (RCTs) and real-world studies have consistently shown that automated insulin delivery (AID) systems improve glycaemic outcomes in individuals with type 1 diabetes.
Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a greater percentage of glucose time in range compared with the use of a sensor-augmented insulin pump. Over the past decade, randomised controlled trials (RCTs) and real-world studies have consistently shown that automated insulin delivery (AID) systems improve glycaemic outcomes in individuals with type 1 diabetes.